Aligned Genetics Inc Cash Flow-to-Debt Ratio
Aligned Genetics Inc cash flow-to-debt ratio. Aligned Genetics Inc (238120) has a Cash Flow-to-Debt Ratio of -0.21x as of September 2025, meaning its operating cash flow of ₩-2.04 Billion could theoretically repay 0% of its total liabilities (₩9.61 Billion) in one year. Check Aligned Genetics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aligned Genetics Inc (2015–2024)
Cash flow-to-debt ratio of Aligned Genetics Inc from 2015 to 2024. Historical debt coverage capacity for Aligned Genetics Inc across 10 annual periods. Check Aligned Genetics Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Aligned Genetics Inc Cash Flow-to-Debt Ratio by Year (2015–2024)
Aligned Genetics Inc cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Aligned Genetics Inc. For the full cash flow conversion analysis, see Aligned Genetics Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.35x | ₩3.07 Billion | ₩8.78 Billion | ▲ +17.9% |
| 2023 | 0.30x | ₩2.85 Billion | ₩9.62 Billion | ▲ +7.3% |
| 2022 | 0.28x | ₩2.22 Billion | ₩8.05 Billion | ▲ +1417.9% |
| 2021 | 0.02x | ₩135.97 Million | ₩7.48 Billion | ▲ +104.8% |
| 2020 | 0.01x | ₩35.67 Million | ₩4.02 Billion | ▼ -95.1% |
| 2019 | 0.18x | ₩659.29 Million | ₩3.65 Billion | ▲ +121.8% |
| 2018 | -0.83x | ₩-1.75 Billion | ₩2.11 Billion | ▼ -57.3% |
| 2017 | -0.53x | ₩-876.75 Million | ₩1.67 Billion | ▲ +22.6% |
| 2016 | -0.68x | ₩-1.14 Billion | ₩1.68 Billion | ▼ -53.8% |
| 2015 | -0.44x | ₩-351.72 Million | ₩796.04 Million | — |